No US FDA AdCom for Corcept's Cushing's drug
This article was originally published in Scrip
Executive Summary
The US FDA has decided not to have its outside advisers scrutinize Corcept Therapeutics Cushing's syndrome drug Corlux (mifepristone), a glucocorticoid receptor type II (GR-II) antagonist, which currently is under review at the agency.